DOI: 10.1101/468934Nov 30, 2018Paper

CD44v6 expression is a novel predictive marker of therapy response and poor prognosis in gastric cancer patients

BioRxiv : the Preprint Server for Biology
Carla PereiraCarla Oliveira


Late diagnosis, modest treatment options and lack of predictive markers of therapy response dictate the poor overall survival (OS) of ~1 year in most gastric cancer (GC) patients. We hypothesized that the level of CD44v6 expression in tumor cells could predict therapy response and prognosis in GC patients. We analyzed a surgical tumor series of GC patients for the extension of CD44v6 membranous immuno-expression, clinical-pathological features, patient survival, and response to therapy. By integrating this information, we assessed the value of CD44v6 expression to predict benefit from current treatment regimens and prognosis in GC patients. We used GC cell lines and mouse xenografts to assess and/validate the biological impact of CD44v6 expression in GC cells behavior. We demonstrated that GC patients whose tumors present higher levels of CD44v6 membranous expression benefit from adding chemotherapy to surgery as opposed to those without CD44v6 expression. Moreover, patients bearing CD44v6\_high tumors presented worse OS than those bearing CD44v6\_absent/low tumors, consolidating the role of CD44v6 expression as an independent factor of poor prognosis in this disease. Finally, our in vitro and patients data pinpoints the CD44v6...Continue Reading

Related Concepts

Biological Markers
Malignant Neoplasm of Stomach
Treatment Protocols
Cell Line, Tumor
Tumor Cells, Malignant
Recurrent Tumor
Operative Surgical Procedures
Neoplastic Cell

Related Feeds

BioRxiv & MedRxiv Preprints

BioRxiv and MedRxiv are the preprint servers for biology and health sciences respectively, operated by Cold Spring Harbor Laboratory. Here are the latest preprint articles (which are not peer-reviewed) from BioRxiv and MedRxiv.